Expression and prognostic significance of gastric-specific annexin A10 in diffuse- and intestinal-type gastric carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 1, 2011, Pages 90-97

  Lu, Su Hsi ^a,c   Chen, Yu Ling ^a   Shun, Chia Tung ^a   Lai, Jung Nien ^c   Peng, Shian Yang ^d   Lai, Po Lin ^b   Hsu, Hey Chi ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

Author keywords

Annexin A10; Gastric cancer; Immunohistochemistry; Survival

Indexed keywords

ANNEXIN; ANNEXIN A10; NUCLEAR PROTEIN; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ANIMAL TISSUE; ARTICLE; BRUNNER GLAND; CANCER STAGING; CONTROLLED STUDY; FEMALE; FETUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; LYMPH NODE METASTASIS; MALE; MINIPIG; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; STOMACH CARCINOMA; STOMACH MUCOSA; SURVIVAL; TISSUE DISTRIBUTION; WOODCHUCK;

EID: 78650370253     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06480.x     Document Type: Article

References (51)

1. Smith PD, Moss SE. Structural evolution of the annexin supergene family. Trends Genet. 1994; 10: 241-6.
2. Horlick KR, Ganjianpour M, Frost SC et al. Annexin-I regulation in response to suckling and rat mammary cell differentiation. Endocrinology 1991; 128: 1574-9.
3. Violette SM, King I, Browning JL et al. Role of lipocortin I in the glucocorticoid induction of the terminal differentiation of a human squamous carcinoma. J. Cell Physiol. 1990; 142: 70-7.
4. Gerke V, Moss SE. Annexins: from structure to function. Physiol. Rev. 2002; 82: 331-71.
5. Ohnishi M, Tokuda M, Masaki T et al. Changes in annexin I and II levels during the postnatal development of rat pancreatic islets. J. Cell Sci. 1994; 107: 2117-25.
6. Masaki T, Tokuda M, Ohnishi M et al. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 1996; 24: 72-81.
7. Morgan RO, Jenkins NA, Gilbert DJ et al. Novel human and mouse annexin A10 are linked to the genome duplications during early chordate evolution. Genomics. 1999; 60: 40-9.
8. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J. Pathol. 2008; 216: 131-40.
9. Morgan RO, Martin-Almedina S, Iglesias JM et al. Evolutionary perspective on annexin calcium-binding domains. Biochim. Biophys. Acta. 2004; 1742: 133-40.
10. Raynal P, Pollard HB. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim. Biophys. Acta. 1994; 1197: 63-93.
11. Bitto E, Cho W. Roles of individual domains of annexin I in its vesicle binding and vesicle aggregation: a comprehensive mutagenesis study. Biochemistry 1998; 37: 10231-7.
12. Wang KL, Wu TT, Resetkova E et al. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin. Cancer Res. 2006; 12: 4598-604.
13. Duncan R, Carpenter B, Main LC et al. Characterisation and protein expression profiling of annexins in colorectal cancer. Br. J. Cancer. 2008; 98: 426-33.
14. Lin CY, Jeng YM, Chou HY et al. Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma. J. Surg. Oncol. 2008; 97: 544-50.
15. Paweletz CP, Ornstein DK, Roth MJ et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 2000; 60: 6293-7.
16. Xin W, Rhodes DR, Ingold C et al. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am. J. Pathol. 2003; 162: 255-61.
17. Emoto K, Sawada H, Yamada Y et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 2001; 21: 1339-45.
18. Esposito I, Penzel R, Chaib-Harrireche M et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J. Pathol. 2006; 208: 673-85.
19. Sharma MR, Koltowski L, Ownbey RT et al. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp. Mol. Pathol. 2006; 81: 146-56.
20. Stewart J, Fleshner N, Cole H et al. Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study. J. Clin. Pathol. 2007; 60: 773-80.
21. Stein T, Price KN, Morris JS et al. Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. Clin. Cancer Res. 2005; 11: 6872-9.
22. Karanjawala ZE, Illei PB, Ashfaq R et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am. J. Surg Pathol. 2008; 32: 188-96.
23. Theobald J, Hanby A, Patel K et al. Annexin VI has tumour-suppressor activity in human A431 squamous epithelial carcinoma cells. Br. J. Cancer. 1995; 71: 786-8.
24. Srivastava M, Torosyan Y, Raffeld M et al. ANXA7 expression represents hormone-relevant tumor suppression in different cancers. Int. J. Cancer. 2007; 121: 2628-36.
25. Liu SH, Lin CY, Peng SY et al. Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am. J. Pathol. 2002; 160: 1831-7.
26. Peng SY, Ou YH, Chen WJ et al. Aberrant expressions of annexin A10 short isoform, osteopontin and α-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int. J. Oncol. 2005; 26: 1053-61.
27. Kim J, Kim MA, Jee CD et al. Reduced expression and homozygous deletion of annexin A10 in gastric carcinoma. Int. J. Cancer. 2009; 125: 1842-50.
28. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol. Biol. 2009; 472: 467-77.
29. Health Department of The Executive Yuan of Taiwan. Cancer Registry Annual Report 2006. Taiwan: Health Department of the Executive Yan of Taiwan; 2009.
30. Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003; 362: 305-15.
31. Ringertz N. The pathology of gastric carcinoma. Natl. Cancer Inst. Monogr. 1967; 25: 275-85.
32. Ming SC. Tumors of the esophagus and stomach. In: Firminger HI, ed. Atlas of Tumor Pathology. Washington, D.C.: Armed Forces Institute of Pathology, 1973.
33. Yokobori T, Mimori K, Iwatsuki M et al. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 2009; 69: 3788-94.
34. Yu J, Tao Q, Cheng YY et al. Promoter methylation of the Wnt/β-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 2009; 115: 49-60.
35. Nekarda H, Schmitt M, Ulm K et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994; 54: 2900-7.
36. Wu MS, Shun CT, Wang HP et al. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology. 1997; 112: 1457-65.
37. Li W, Yu CP, Xia JT et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin. Cancer Res. 2009; 15: 1393-9.
38. Chen CN, Chang CC, Su TE et al. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann. Surg. Oncol. 2009; 16: 524-33.
39. Oki M, Yamamoto H, Taniguchi H et al. Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers. World J. Gastroenterol. 2008; 14: 5650-6.
40. Hayashi M, Inokuchi M, Takagi Y et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 2008; 14: 7843-9.
41. Jeng YM, Wang TH, Lu SH et al. Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br. J. Surg. 2009; 96: 66-73.
42. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta. Pathol. Microbiol. Scand. 1965; 64: 31-49.
43. Mori M, Sakaguchi H, Akazawa K et al. Correlation between metastatic site, histological type, and serum tumor markers of gastric carcinoma. Hum. Pathol. 1995; 26: 504-8.
44. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumours. International Union Against Cancer, 5th edn. New York: John Wiley & Sons, 1997.
45. Katai H, Yoshimura K, Maruyama K et al. Evaluation of the New International Union Against Cancer TNM staging for gastric carcinoma. Cancer 2000; 88: 1796-800.
46. Schumacher U, Duku M, Katoh M et al. Histochemical similarities of mucins produced by Brunner's glands and pyloric glands: a comparative study. Anat. Rec. A Discov. Mol. Cell Evol. Biol. 2004; 278: 540-50.
47. Gurbuz Y, Kahlke V, Kloppel G. How do gastric carcinoma classification systems relate to mucin expression patterns? An immunohistochemical analysis in a series of advanced gastric carcinomas. Virchows Arch. 2002; 440: 505-11.
48. Yamashiro K, Suzuki H, Nagayo T. Electron microscopic study of signet-ring cells in diffuse carcinoma of the human stomach. Virchows Arch. A Pathol. Anat. Histol. 1977; 374: 275-84.
49. Fiocca R, Villani L, Tenti P et al. Characterization of four main cell types in gastric cancer: foveolar, mucopeptic, intestinal columnar and goblet cells. An histopathologic, histochemical and ultrastructural study of "early" and "advanced" tumours. Pathol. Res. Pract. 1987; 182: 308-25.
50. Sugano H, Nakamura K, Kato Y. Pathological studies of human gastric cancer. Acta. Pathol. Jpn. 1982; 32 (Suppl. 2): 329-47.
51. van Baal JW, Milana F, Rygiel AM et al. A comparative analysis by SAGE of gene expression profiles of esophageal adenocarcinoma and esophageal squamous cell carcinoma. Cell Oncol. 2008; 30: 63-75.